
STRO Stock Forecast & Price Target
STRO Analyst Ratings
Bulls say
Sutro Biopharma is well-positioned in the ADC market with their innovative platform and promising candidate STRO-004, backed by strong partnerships and a focus on stable linker technology. The company's financials and cash position provide a solid base for future growth, making it an attractive investment opportunity.
Bears say
Sutro Biopharma is undergoing a pivot in its business strategy, focusing on its proprietary integrated cell-free protein synthesis platform, XpressCF, to develop novel treatments for cancer and autoimmune disorders. However, with a significant portion of its pipeline still in early stages of development and limited clinical data, there are concerns about the company's ability to successfully execute on its clinical programs. This, coupled with the fact that the company is heavily reliant on partnerships for revenue, indicates a high level of risk for investors. Additionally, Sutro's current valuation seems high based on traditional metrics, which suggests limited upside potential for the stock in the near term.
This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
STRO Analyst Forecast & Price Prediction
Start investing in STRO
Order type
Buy in
Order amount
Est. shares
0 shares